Total Payments
$17,383
2024 Payments
$1,790
Companies
9
Transactions
19
Medicare Patients
683
Medicare Billing
$192,270
Payment Breakdown by Category
Research$12,908 (74.3%)
Consulting$4,090 (23.5%)
Food & Beverage$385.08 (2.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $12,908 | 11 | 74.3% |
| Consulting Fee | $4,090 | 5 | 23.5% |
| Food and Beverage | $385.08 | 3 | 2.2% |
Payments by Type
Research
$12,908
11 transactions
General
$4,475
8 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $7,800 | 4 | $0 (2021) |
| Novartis Pharmaceuticals Corporation | $4,923 | 5 | $0 (2020) |
| MITSUBISHI TANABE PHARMA AMERICA, INC. | $1,790 | 2 | $0 (2024) |
| Boehringer Ingelheim International GmbH | $1,300 | 2 | $0 (2021) |
| Merck Sharp & Dohme Corporation | $1,000 | 1 | $0 (2020) |
| E.R. Squibb & Sons, L.L.C. | $185.00 | 2 | $0 (2018) |
| GlaxoSmithKline, LLC. | $162.10 | 1 | $0 (2017) |
| Celgene Corporation | $114.10 | 1 | $0 (2017) |
| Daiichi Sankyo Inc. | $108.88 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,790 | 2 | MITSUBISHI TANABE PHARMA AMERICA, INC. ($1,790) |
| 2021 | $4,470 | 3 | PFIZER INC. ($3,820) |
| 2020 | $8,443 | 5 | PFIZER INC. ($3,980) |
| 2019 | $458.40 | 1 | NOVARTIS PHARMACEUTICALS CORPORATION ($458.40) |
| 2018 | $1,837 | 5 | Novartis Pharmaceuticals Corporation ($1,652) |
| 2017 | $385.08 | 3 | GlaxoSmithKline, LLC. ($162.10) |
All Payment Transactions
19 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/12/2024 | MITSUBISHI TANABE PHARMA AMERICA, INC. | — | Consulting Fee | Cash or cash equivalent | $895.00 | General |
| 07/26/2024 | MITSUBISHI TANABE PHARMA AMERICA, INC. | — | Consulting Fee | Cash or cash equivalent | $895.00 | General |
| 10/08/2021 | PFIZER INC. | TALZENNA (Drug) | — | In-kind items and services | $3,200.00 | Research |
| Study: TALAZOPARIB CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 09/17/2021 | PFIZER INC. | TALZENNA (Drug) | — | In-kind items and services | $620.00 | Research |
| Study: TALAZOPARIB CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 01/08/2021 | Boehringer Ingelheim International GmbH | — | Consulting Fee | Cash or cash equivalent | $650.00 | General |
| 12/20/2020 | Boehringer Ingelheim International GmbH | — | Consulting Fee | Cash or cash equivalent | $650.00 | General |
| 09/29/2020 | PFIZER INC. | TALZENNA (Drug) | — | In-kind items and services | $780.00 | Research |
| Study: TALAZOPARIB CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 08/20/2020 | PFIZER INC. | TALZENNA (Drug) | — | In-kind items and services | $3,200.00 | Research |
| Study: TALAZOPARIB CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 02/24/2020 | Novartis Pharmaceuticals Corporation | DOVITINIB LACTATE (Drug) | — | In-kind items and services | $2,813.00 | Research |
| Study: RESEARCH RELATED PUBLICATIONS SUPPORT | ||||||
| 02/14/2020 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| Category: ONCOLOGY | ||||||
| 02/12/2019 | NOVARTIS PHARMACEUTICALS CORPORATION | PDR001 (Drug) | — | In-kind items and services | $458.40 | Research |
| Study: RESEARCH RELATED PUBLICATIONS SUPPORT | ||||||
| 10/17/2018 | E.R. Squibb & Sons, L.L.C. | — | — | In-kind items and services | $95.00 | Research |
| Study: A Phase 1 2a Study of BMS 986253 in Combination with Nivolumab in Advanced Cancers | ||||||
| 09/20/2018 | E.R. Squibb & Sons, L.L.C. | — | — | In-kind items and services | $90.00 | Research |
| Study: An Investigational Immunotherapy Study of BMS 986249 Alone and in Combination With Nivolumab in Solid Cancers That Are Advanced or Have Spread | ||||||
| 06/04/2018 | NOVARTIS PHARMACEUTICALS CORPORATION | PDR001 (Drug) | — | In-kind items and services | $1,117.17 | Research |
| Study: RESEARCH RELATED PUBLICATION SUPPORT | ||||||
| 02/13/2018 | NOVARTIS PHARMACEUTICALS CORPORATION | PDR001 (Drug) | — | In-kind items and services | $382.00 | Research |
| Study: RESEARCH RELATED PUBLICATION SUPPORT | ||||||
| 02/13/2018 | Novartis Pharmaceuticals Corporation | GWN323X (Drug) | — | In-kind items and services | $152.80 | Research |
| Study: RESEARCH RELATED PUBLICATION SUPPORT | ||||||
| 11/21/2017 | GlaxoSmithKline, LLC. | — | Food and Beverage | In-kind items and services | $162.10 | General |
| 10/27/2017 | Daiichi Sankyo Inc. | — | Food and Beverage | In-kind items and services | $108.88 | General |
| 06/04/2017 | Celgene Corporation | Abraxane (Drug) | Food and Beverage | In-kind items and services | $114.10 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| TALAZOPARIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $7,800 | 4 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | Novartis Pharmaceuticals Corporation | $2,813 | 1 |
| RESEARCH RELATED PUBLICATION SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $1,499 | 2 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $458.40 | 1 |
| RESEARCH RELATED PUBLICATION SUPPORT | Novartis Pharmaceuticals Corporation | $152.80 | 1 |
| A Phase 1 2a Study of BMS 986253 in Combination with Nivolumab in Advanced Cancers | E.R. Squibb & Sons, L.L.C. | $95.00 | 1 |
| An Investigational Immunotherapy Study of BMS 986249 Alone and in Combination With Nivolumab in Solid Cancers That Are Advanced or Have Spread | E.R. Squibb & Sons, L.L.C. | $90.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 186 | 447 | $225,528 | $46,580 |
| 2022 | 6 | 210 | 547 | $254,574 | $59,764 |
| 2021 | 6 | 167 | 508 | $233,729 | $57,306 |
| 2020 | 4 | 120 | 324 | $145,045 | $28,621 |
Total Patients
683
Total Services
1,826
Medicare Billing
$192,270
Procedure Codes
21
All Medicare Procedures & Services
21 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 126 | 370 | $197,127 | $39,965 | 20.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 18 | 26 | $6,982 | $1,912 | 27.4% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 13 | 14 | $8,324 | $1,870 | 22.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 12 | 12 | $8,858 | $1,609 | 18.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 17 | 25 | $4,237 | $1,224 | 28.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 126 | 429 | $219,876 | $49,681 | 22.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 28 | 55 | $9,022 | $2,667 | 29.6% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 15 | 15 | $8,284 | $2,434 | 29.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 16 | 16 | $8,622 | $2,418 | 28.0% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 14 | 21 | $5,943 | $1,762 | 29.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 11 | 11 | $2,827 | $802.22 | 28.4% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 94 | 418 | $206,526 | $49,014 | 23.7% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 14 | 14 | $7,493 | $2,140 | 28.6% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 11 | 12 | $6,400 | $1,970 | 30.8% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 22 | 34 | $5,358 | $1,855 | 34.6% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 12 | 16 | $4,528 | $1,256 | 27.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 14 | 14 | $3,424 | $1,071 | 31.3% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 76 | 262 | $125,092 | $22,532 | 18.0% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 14 | 15 | $7,707 | $2,511 | 32.6% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 13 | 25 | $7,075 | $2,156 | 30.5% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 17 | 22 | $5,171 | $1,421 | 27.5% |
About Dr. Sarina Piha-Paul, M.D
Dr. Sarina Piha-Paul, M.D is a Internal Medicine healthcare provider based in Houston, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/22/2008. The National Provider Identifier (NPI) number assigned to this provider is 1235381179.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Sarina Piha-Paul, M.D has received a total of $17,383 in payments from pharmaceutical and medical device companies, with $1,790 received in 2024. These payments were reported across 19 transactions from 9 companies. The most common payment nature is "" ($12,908).
As a Medicare-enrolled provider, Piha-Paul has provided services to 683 Medicare beneficiaries, totaling 1,826 services with total Medicare billing of $192,270. Data is available for 4 years (2020–2023), covering 21 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Medical Oncology
- Location Houston, TX
- Active Since 10/22/2008
- Last Updated 05/08/2023
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1235381179
Products in Payments
- TALZENNA (Drug) $7,800
- DOVITINIB LACTATE (Drug) $2,813
- PDR001 (Drug) $1,958
- KEYTRUDA (Biological) $1,000
- GWN323X (Drug) $152.80
- Abraxane (Drug) $114.10
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Houston
Stephen Pappas, M.d, M.D
Internal Medicine — Payments: $1.6M
Internal Medicine $1.6M
Mohamed Othman, Md, MD
Internal Medicine — Payments: $1.1M
Internal Medicine $1.1M
Dr. Aung Naing, Md, MD
Internal Medicine — Payments: $925,146
Internal Medicine $925,146
Miguel Escobar, M.d, M.D
Internal Medicine — Payments: $924,228
Internal Medicine $924,228
Dr. Christie Ballantyne, Md, MD
Internal Medicine — Payments: $815,154
Internal Medicine $815,154
John Heymach, M.d, M.D
Internal Medicine — Payments: $786,947
Internal Medicine $786,947